BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update
Brainstorm Cell Therapeutics Inc. (BCLI)
Last brainstorm cell therapeutics inc. earnings: 11/14 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.brainstorm-cell.com
Company Research
Source: GlobeNewswire
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: Special High-level FDA Meeting, Continued Progress in NurOwn® ALS Phase 3 Trialand Progressive MS Phase 2 Trial, ALS Phase 3 Trial Enrollment Update NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today financial results for the second quarter ended June 30, 2019 and recent corporate updates. “We continue to actively enroll patients in our Phase 3 trial of NurOwn® in ALS (Amyotrophic Lateral Sclerosis) and in our Phase 2 trial of NurOwn® in Progressive MS (Multiple Sclerosis) in several of the preeminent U.S. medical institutions,” commented Chaim Lebovits, President and Chief Executive Officer of BrainStorm Cell Therapeutics. “We anticipate completing enrollment in our Phase 3 ALS study during the second week of October 2019 and expect top-line results b
Show less
Read more
Impact Snapshot
Event Time:
BCLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCLI alerts
High impacting Brainstorm Cell Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCLI
News
- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial ManufacturingPR Newswire
BCLI
Earnings
- 11/14/24 - Miss
BCLI
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 11/14/24 - Form SC
- BCLI's page on the SEC website